People · Operator
Named in public records as an officer, director or promoter · active 2016–2025 · Biotechnology, Pharma, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Abcuro, Inc. | — | Biotechnology | Series D+ | $225.9M | $719.4M | 2020 |
| Star Therapeutics LLC | — | Pharma | Series D+ | $125.0M | $936.1M | 2025 |
| Escient Pharmaceuticals Inc | — | Biotechnology | Series C | $108.8M | $995.9M | 2020 |
| Expansion Therapeutics, Inc. | — | Pharmaceuticals | Series C | $78.3M | $1.1B | 2016 |
| Character Biosciences, Inc. | — | Biotechnology | Series C | $57.0M | $50.5M | 2025 |
| Matchpoint Therapeutics Inc. | — | Pharmaceuticals | Series C | $42.0M | $672.3M | 2022 |
Jason Hafler at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jason Hafler on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| Andrew Schwab | 1 | 16 |
| Beth Seidenberg | 1 | 15 |
| Bruce Booth | 1 | 12 |
| SCOTT ROCKLAGE | 1 | 9 |
| John Edwards | 1 | 8 |
| Peter Hirth | 1 | 7 |
| Andre Turenne | 1 | 7 |
| Maha Katabi | 1 | 6 |
| Julius Knowles | 1 | 5 |
| Daniel Becker | 1 | 5 |
| Paul Stone | 1 | 5 |
| Vivek Garipalli | 1 | 5 |
| Nancy Stagliano | 1 | 5 |
| Matthew Fust | 1 | 4 |
| Kevin Raidy | 1 | 4 |
| Marcus Boehm | 1 | 3 |
| Yujiro Hata | 1 | 3 |
| Kevin Forrest | 1 | 3 |
| Scott Robertson | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.